CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05105542
NCT05105542Phase 1Completed
CompareCT.gov

Muscarinic M1 Receptor Availability and Cognition in Schizophrenia

Yale University·interventional·Posted Nov 3, 2021·Updated Nov 12, 2024

In Brief

A Phase 1 clinical trial evaluating 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor and PET Scan for Schizophrenia and 2 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This exploratory study seeks to examine M1 receptor availability in SZ patients and to relate M1 receptor availability to proximal and distal measures of cognitive performance, namely evoked ɣ oscillations in the EEG and verbal memory. Furthermore, the relationship between hippocampal \[11C\]EMO availability (BPND), evoked ɣ oscillations, verbal memory, and measures of illness severity will be explored.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Healthy
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedNov 3, 2021
Enrollment StartApr 20, 2021
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.7 years ago

Interventions

11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptordrug

The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.

PET Scandevice

PET scanner with high sensitivity and resolution available for human brain imaging